Nasdaq

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter ...

- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...
Yahoo Finance

Paradigm’s My Surgery Named "Best Patient Education Solution" in 2026 MedTech Breakthrough Awards Program

TAMPA, Fla., May 07, 2026--(BUSINESS WIRE)--Paradigm, a specialty care management organization focused on delivering value-based solutions to improve outcomes for patients, payers, and providers, ...
Stockhouse

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter ...

“Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program is a truly significant and gratifying milestone,” said ...
Morningstar

Paradigm’s My Surgery Named “Best Patient Education Solution” in 2026 MedTech Breakthrough Awards Program

Paradigm, a specialty care management organization focused on delivering value-based solutions to improve outcomes for patients, payers, and providers, today announced that My Surgery has been ...